Previous 10 | Next 10 |
This study, which utilized the gold standard method of stable isotopes, reinforces that NMN cannot cross the cell membrane directly and must first be converted to NR ChromaDex Corp. (NASDAQ:CDXC), a global authority on Nicotinamide Adenine Dinucleotide (NAD + ) research and healthy ...
2023-08-09 20:32:05 ET ChromaDex Corporation (CDXC) Q2 2023 Earnings Call Transcript August 09, 2023 04:30 PM ET Company Participants Kendall Knysch - Director, Media Relations Rob Fried - Chief Executive Officer Brianna Gerber - Chief Financial Officer Con...
2023-08-09 16:27:15 ET ChromaDex press release ( NASDAQ: CDXC ): Q2 GAAP EPS of -$0.03 beats by $0.01 . Revenue of $20.3M (+21.6% Y/Y) beats by $0.78M . Total net sales were $20.3 million, with $16.9 million from Tru Niagen, up 21% and 16% from the prior year q...
Strong quarter with total net sales of $20.3 million, a gross margin of 60.8% and a net loss of $2.2 million while achieving a positive Adjusted EBITDA of $0.2 million and positive operating cash flows for the three months ended June 30, 2023. ChromaDex Corp. (NASDAQ:CDXC) today announc...
This partnership positions Tru Niagen for accelerated global expansion given nearly 90% of iHerb sales are outside of the U.S. ChromaDex Corp. (NASDAQ:CDXC), a global bioscience company dedicated to healthy aging, announces the appointment of the world’s number one online destina...
Presentations and live Q&A to take place on Monday, August 14 and Wednesday, August 16 ChromaDex Corp. (NASDAQ:CDXC), a global authority on Nicotinamide Adenine Dinucleotide (NAD+) research and healthy aging, announced today that they will be participating in Renmark Financial Commu...
ChromaDex Corp. (NASDAQ:CDXC), a global bioscience company dedicated to healthy aging, announced that it will hold a conference call on Wednesday, August 9, 2023 at 4:30 p.m. ET to discuss its financial results for the second quarter, which ended on June 30, 2023. The financial results will be ...
Abstracts recently published in the Association for Research in Vision and Ophthalmology (ARVO) journal showcase NR, one of the most efficient and well-researched NAD+ precursors, prevented the worsening of visual field sensitivity in glaucoma patients, and builds on research demonstrating decrea...
Through CERP™, over 275 global research agreements with 235+ independent, expert investigators are uncovering the full potential of NAD+ by researching ChromaDex’s Niagen® ingredient, patented nicotinamide riboside (NR), one of the most studied and efficient modern NAD+ precurs...
ChromaDex Corp. (NASDAQ:CDXC) today announced that it will be participating at the 13th Annual LD Micro Invitational at the Luxe Sunset Boulevard Hotel, California on June 6th-8th, 2023. The event is expected to feature 150+ companies, presenting in half-hour increments, as well as private 1:1 ...
News, Short Squeeze, Breakout and More Instantly...
ChromaDex Corporation Company Name:
CDXC Stock Symbol:
NASDAQ Market:
ChromaDex Corporation Website:
U.S. FDA-registered 503B outsourcing facility, Wells Pharma of Houston, will compound and distribute Niagen (nicotinamide riboside chloride) IV and injections to Cenegenics, Clean Market/NutriDrip, Drip Hydration, EXTEN IV, Kensho Wellbeing, The NAD MD, Next Health, The Remedy Room, Restore Hyper...
ChromaDex continues to drive innovation and growth with its proprietary Tru Niagen ® supplement, backed by strong financial performance and a robust intellectual property portfolio ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD +...
NR improved the six-minute walking distance and treadmill walking time for those with PAD ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD + ) research, shares results from a milestone phase II clinical study showcasing the promising effe...